# RNA-Based Biomarkers for Diagnostic Discrimination of Ischemic and Hemorrhagic Stroke: A Systematic Review

**Authors:** Jan Emmerich, Aditya Chanpura, Frank C. Barone, Alison E. Baird, Tyler M. Lu, Kristian Barlinn, Ben W. M. Illigens, Arturo Tamayo, Hagen B. Huttner, Timo Siepmann

PMC · DOI: 10.3390/jcm15041392 · 2026-02-10

## TL;DR

This review explores RNA biomarkers in blood that could help distinguish between two types of stroke, ischemic and hemorrhagic, for faster and more accurate diagnosis.

## Contribution

The study systematically reviews RNA-based biomarkers for their potential to differentiate between ischemic and hemorrhagic stroke.

## Key findings

- Several RNA biomarkers, including miRNA-124-3p and lncRNA XIST, showed significant differences between ischemic and hemorrhagic stroke.
- Methodological heterogeneity across studies limits the ability to perform a meta-analysis.
- Machine learning techniques demonstrated potential in clustering RNA biomarkers to distinguish stroke types.

## Abstract

Background: Diagnostic discrimination between ischemic stroke (IS) and hemorrhagic stroke (HS) is required for successful intervention with time-critical acute treatments. The available data on blood-based RNA biomarkers and discrimination between IS and HS are limited. This systematic review aimed to examine and summarize the existing literature on potentially useful blood-based RNA biomarkers that may aid in preclinical acute diagnosis. Methods: We systematically reviewed the literature on the ability of blood-based RNA biomarkers to discriminate between IS and HS according to PRISMA guidelines. We searched PubMed, EMBASE, The Cochrane Library, and The Web of Science for eligible randomized controlled trials, observational studies, and case–control studies published in the English language without time limitation. The risk of bias was evaluated using the Newcastle–Ottawa Scale. Results: We included eight studies with a total of 728 patients (436 with IS and 292 with HS) in our review. The study quality was good in five and fair in three investigations. No meta-analysis was performed due to high heterogeneity in methods and study endpoints. Reported biomarkers include miRNA-124-3p, miRNA-16, miRNA-340-5p, lncRNA XIST (X-inactive specific transcript), PFKFB3 mRNA (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase), tRNA derivatives, tRNA fragments, extracellular miRNAs, transcriptome changes, and MCEMP1 gene expression. Assessment techniques varied widely across studies, ranging from RNA sequencing to qPCR, microarray, human transcriptome array, and ELISA. MicroRNA-124-3p, miRNA-340-5p, lncRNA XIST, PFKFB3 mRNA, and MCEMP1 gene expression differed significantly between IS and HS. In one study, principal component analysis and unsupervised learning demonstrated the utility of hierarchical clustering of differentially expressed exons to discriminate between HS and IS. Conclusions: This review demonstrates the utility of single RNA-based targets and clusters that may have diagnostic value in distinguishing IS from HS. However, the current body of evidence is limited by considerable methodological heterogeneity between studies. Registration: This systematic review was prospectively registered on PROSPERO on 21 April 2023 (CRD42023411203).

## Linked entities

- **Genes:** PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) [NCBI Gene 5209], MCEMP1 (mast cell expressed membrane protein 1) [NCBI Gene 199675], XIST (X inactive specific transcript) [NCBI Gene 7503]
- **Diseases:** ischemic stroke (MONDO:1060198), hemorrhagic stroke (MONDO:1060199)

## Full-text entities

- **Genes:** APOC1 (apolipoprotein C1) [NCBI Gene 341] {aka APOC1B, Apo-CI, ApoC-I, apo-CIB, apoC-IB}, MAST2 (microtubule associated serine/threonine kinase 2) [NCBI Gene 23139] {aka MAST205, MTSSK}, ENO2 (enolase 2) [NCBI Gene 2026] {aka HEL-S-279, NSE}, XIST (X inactive specific transcript) [NCBI Gene 7503] {aka DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, TGFA (transforming growth factor alpha) [NCBI Gene 7039] {aka TFGA}, SEPTIN5 (septin 5) [NCBI Gene 5413] {aka CDCREL, CDCREL-1, CDCREL1, H5, HCDCREL-1, PNUTL1}, FCER1A (Fc epsilon receptor Ia) [NCBI Gene 2205] {aka FCE1A, FCERIA, FcERI}, MIR124-3 (microRNA 124-3) [NCBI Gene 406909] {aka MIRN124-3, MIRN124A3, mir-124-3}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, HDC (histidine decarboxylase) [NCBI Gene 3067], GDE1 (glycerophosphodiester phosphodiesterase 1) [NCBI Gene 51573] {aka 363E6.2, MIR16}, KRCC1 (lysine rich coiled-coil 1) [NCBI Gene 51315] {aka CHBP2, HLY}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, MCEMP1 (mast cell expressed membrane protein 1) [NCBI Gene 199675] {aka C19orf59}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, SIRAL2 (SIR2 antiphage like 2) [NCBI Gene 55007] {aka C22orf8, FAM118A}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, S100B (S100 calcium binding protein B) [NCBI Gene 6285] {aka NEF, S100, S100-B, S100beta}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, DAPK1 (death associated protein kinase 1) [NCBI Gene 1612] {aka DAPK, ROCO3}, VHL (von Hippel-Lindau tumor suppressor) [NCBI Gene 7428] {aka HRCA1, RCA1, VHL1, pVHL}, CSF3 (colony stimulating factor 3) [NCBI Gene 1440] {aka C17orf33, CSF3OS, GCSF}, F2R (coagulation factor II thrombin receptor) [NCBI Gene 2149] {aka CF2R, HTR, PAR-1, PAR1, TR}, PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) [NCBI Gene 5209] {aka IPFK2, PFK2, iPFK-2}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, E2F1 (E2F transcription factor 1) [NCBI Gene 1869] {aka E2F-1, RBAP1, RBBP3, RBP3}, MIR340 (microRNA 340) [NCBI Gene 442908] {aka MIRN340, hsa-mir-340, mir-340}, FYN (FYN proto-oncogene, Src family tyrosine kinase) [NCBI Gene 2534] {aka SLK, SYN, p59-FYN}, OSM (oncostatin M) [NCBI Gene 5008]
- **Diseases:** TIA (MESH:D002546), Intracranial Hemorrhage (MESH:D020300), LV (MESH:D018487), Hyperlipoproteinemia (MESH:D006951), hemorrhagic (MESH:D006470), inflammatory bowel disease (MESH:D015212), Vessel infarction (MESH:D007238), cardiac dysfunction (MESH:D006331), type 1 diabetes (MESH:D003922), LAC (MESH:C537004), Stroke (MESH:D020521), multiple sclerosis (MESH:D009103), neurological disorders (MESH:D009461), acute IS (MESH:D000083242), migraine (MESH:D008881), systemic lupus erythematosus (MESH:D008180), Lacunar Stroke (MESH:D059409), autoimmune, neurological, and infectious diseases (MESH:D003141), inflammation (MESH:D007249), Disease (MESH:D004194), injury to (MESH:D014947), long-term disability (MESH:D000088562), amyotrophic lateral sclerosis (MESH:D000690), hyperlipidemia (MESH:D006949), rheumatoid arthritis (MESH:D001172), HLP (MESH:C538377), death (MESH:D003643), hyperinsulinemia (MESH:D006946), Hypertension (MESH:D006973), atherosclerosis (MESH:D050197), Parkinson's (MESH:D010300), ICH (MESH:D002543), SAH (MESH:D013345), cardiovascular conditions (MESH:D002318), myocardial infarction (MESH:D009203), Alzheimer's (MESH:D000544), Large Vessel Occlusive Stroke (MESH:C536223), cancer (MESH:D009369), IS (MESH:D002544), Diabetes mellitus (MESH:D003920), ischemic heart disease (MESH:D017202), atrial fibrillation (MESH:D001281), Cardio Embolic Infarction (MESH:D000083262), neuroinflammation (MESH:D000090862), hem (MESH:C535858), HS (MESH:D000083302)
- **Chemicals:** lipid (MESH:D008055), glucose (MESH:D005947), 4HLP (-)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12942304/full.md

---
Source: https://tomesphere.com/paper/PMC12942304